Bacaksız Elif Gram, Hakim Gozde Dervis, Yıldız Coskun, Akar Harun
Department of Internal Medicine, Tepecik Research and Training Hospital, Izmir, Turkey.
Department of Gastroenterology, Tepecik Training and Research Hospital, Izmir, Turkey.
Prz Gastroenterol. 2022;17(2):138-145. doi: 10.5114/pg.2022.116373. Epub 2022 May 19.
Standard triple therapy used to be the first-line treatment for (Hp) infection, but today it is a treatment regimen with a low eradication rate due to increasing resistance to the antibiotics included in the triple therapy.Aim: To compare the eradication rates of dual treatment regimens and quadruple treatment regimens.
Patients over 18 years of age, who were indicated to undergo upper gastrointestinal system (GIS) endoscopy for any reason, had their upper gastrointestinal endoscopy performed, were detected to have Hp as a result of the histopathological evaluation of the biopsy material, and in whom eradication control was also performed by histopathological evaluation, were included in the study. These patients were divided into 4 groups, each containing 50 people.
Considering the eradication rates of Hp-positive patients according to different treatment options, 78% ( = 39) of the patients in Group 1 were eradicated after the treatment while 66% ( = 33) of the patients in Group 3, 58% of the patients in Group 2 ( = 29), and 58% ( = 29) of the patients in Group 4 had Hp negative results after treatment. When high-dose dual treatments were compared, the highest eradication rate was obtained with rabeprazole, but no statistically significant difference was detected ( = 0.11).
This is the first study to include dual therapies consisting of 3 different PPIs at the same time. The low eradication rates obtained in our study suggest that the determination of individualized treatment strategies in which CYP2C19 polymorphism is detected may result in higher eradication rates.
标准三联疗法曾是幽门螺杆菌(Hp)感染的一线治疗方法,但如今由于对三联疗法中所含抗生素的耐药性增加,它已成为一种根除率较低的治疗方案。
比较双联治疗方案和四联治疗方案的根除率。
纳入18岁以上因任何原因需接受上消化道系统(GIS)内镜检查的患者,对其进行上消化道内镜检查,通过活检材料的组织病理学评估检测出Hp,且也通过组织病理学评估进行根除控制。这些患者被分为4组,每组50人。
根据不同治疗方案考虑Hp阳性患者的根除率,治疗后第1组78%(n = 39)的患者Hp被根除,第3组66%(n = 33)的患者、第2组58%(n = 29)的患者以及第4组58%(n = 29)的患者治疗后Hp检测结果为阴性。比较高剂量双联治疗时,雷贝拉唑的根除率最高,但未检测到统计学上的显著差异(P = 0.11)。
这是第一项同时纳入由3种不同质子泵抑制剂组成的双联疗法的研究。我们研究中获得的低根除率表明,检测CYP2C19基因多态性并制定个体化治疗策略可能会提高根除率。